1-2 of 2
Giulia Marzocchi, BD
Close
Sort by
Journal Articles

Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell’Adulto) CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.

Gianantonio Rosti, MD, Fausto Castagnetti, MD, Marilina Amabile, BD, Nicoletta Testoni, BD, Angela Poerio, BD, Giulia Marzocchi, BD, Massimo Breccia, MD, Francesca Palandri, MD, Tamara Intermesoli, MD, Fabio Stagno, MD, Giorgina Specchia, MD, Elisabetta Abruzzese, MD, Panagiota Giannoulia, MD, Giuseppe Saglio, MD, Fabrizio Pane, MD, Francesca Rancati, BD, Arnon Nagler, MD, Ibrahim Haznedaroglu, MD, Kimmo PorkKa, MD, Henrik Hjorth-Hansen, MD, Johan L. Nielsen, MD, Bengt Simonsson, MD, Giovanni Martinelli, MD, Michele Baccarani, MD
Journal: Blood
Blood (2006) 108 (11): 4776.
https://doi.org/10.1182/blood.V108.11.4776.4776
Published: 2006
Journal Articles

Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).

Fausto Castagnetti, MD, Giulia Marzocchi, BD, Simona Luatti, BD, Francesca Buontempo, BD, Carmen Baldazzi, BD, Francesca Palandri, MD, Panagiota Giannoulia, MD, Marilina Amabile, BD, Ilaria Iacobucci, BD, Marco Mancini, MD, Ursula Giussani, MD, Giorgina Specchia, MD, Antonio Cuneo, MD, Emilia Gugliano, MD, Simonetta Kerim, MD, Bruno Modaferri, MD, Elisabetta Abruzzese, MD, Giovanni Martinelli, MD, Nicoletta Testoni, BD, Gianantonio Rosti, MD, Michele Baccarani, MD
Journal: Blood
Blood (2006) 108 (11): 2112.
https://doi.org/10.1182/blood.V108.11.2112.2112
Published: 2006